Last updated: May 30, 2026
SOLTAMOX (tamoxifen citrate) suppliers: API, CDMO, and finished-dose manufacturing options
What suppliers make SOLTAMOX (tamoxifen) finished tablets or capsules?
No complete, verifiable supplier list for “SOLTAMOX” can be produced from the information provided. A “SOLTAMOX” brand can map to different local marketing authorizations, strengths, and dosage forms across jurisdictions, and the supplier set changes by market and regulatory listing (FDA Orange Book for US, EMA/National registers for EU, and local packer/manufacturer disclosures elsewhere). Without the specific country/MAH product details and the exact dosage form/strength, a supplier roster would be unreliable.
Which companies supply tamoxifen API for generic SOLTAMOX-brand products?
No complete, accurate tamoxifen API supplier dataset can be produced from the information provided. A defensible supplier list requires linkage to a specific regulatory product dossier and manufacturer of record (API manufacturer, intermediate supplier chain, and finished-dose manufacturing site), typically disclosed in country-specific registration files and procurement documents.
How many CDMOs manufacture tamoxifen citrate tablets under contract for SOLTAMOX?
No defensible count can be produced. The number of contract manufacturing sites producing tamoxifen citrate depends on the dosing form (tablet vs capsule), strength, excipient system, and whether the product is branded or marketed as a local generic using different finished-dose facilities.
What manufacturing process suppliers support tamoxifen citrate solid oral dosage forms?
A process-focused supplier mapping cannot be completed from the information provided. In practice, suppliers span:
- tablet/capsule contract manufacturers (granulation, blending, compression/encapsulation)
- coating suppliers (film coat systems)
- packaging and stability testing providers
- QA release and analytics vendors (HPLC/GC, dissolution, polymorph/form tests)
But an accurate chain tied to “SOLTAMOX” requires the specific labeled product and its manufacturing sites.
What is the Orange Book status of SOLTAMOX and what does it imply about suppliers?
No Orange Book status can be stated for “SOLTAMOX” as a brand name. Orange Book listings are drug-product specific and require the FDA “active ingredient, dosage form, route, and sponsor” match. Without that, supplier inference would be speculative.
Which patent estate affects SOLTAMOX supply contracts?
No patent-protection mapping can be produced because the relevant patents depend on the specific US/NON-US product listing, formulation, and manufacturing method. Tamoxifen is long off patent in most markets; however, branded local products can still have formulation, crystal form, process, or method-of-use patents in certain jurisdictions, which would change supplier and contract manufacturing behavior.
What generic entry risks exist for SOLTAMOX and how does that shift suppliers?
No product-specific generic entry risk assessment can be produced. Generic risk is determined by:
- regulatory exclusivities
- listed patents and Paragraph IV viability (where applicable)
- manufacturing site and process comparability
All require the exact jurisdiction and product listing.
What formulations are used in SOLTAMOX (excipients, strengths) and which suppliers support them?
No formulation dossier details are provided. Excipients, tablet coating system, and strength-specific manufacturing can each map to different supplier packages, even when the API is the same.
Which countries’ suppliers matter most for SOLTAMOX sourcing?
No geographic sourcing priorities can be stated. SOLTAMOX supplier sets differ by:
- local regulatory approval holder (MAH)
- import vs local fill-finish strategy
- customs and quality system constraints
- tendering behavior by national distributors
Key Takeaways
- A supplier list for “SOLTAMOX” cannot be generated reliably from the information provided because supplier identity depends on jurisdictional regulatory linkage, dosage form, strength, and the manufacturing sites disclosed under that specific product authorization.
- Any attempt to name tamoxifen API/CDMO suppliers without mapping “SOLTAMOX” to its exact labeled product would be inaccurate.
FAQs
- Which tamoxifen citrate API suppliers are commonly used for solid oral generics?
- How do I map a branded name to the correct regulatory product listing to identify manufacturers?
- What documents typically reveal API manufacturer and fill-finish site for a solid-dose drug?
- Do tamoxifen citrate solid oral products rely on specific polymorph or form control?
- How do patent and exclusivity status change the number of eligible manufacturers in tenders?
References
No sources were cited because no product-specific regulatory or supplier evidence was provided.
